Creation of the production unit of 192Ir, for sealed sources.
Construction of the first cyclotron.
Pharmaceutical approval of the company.
Creation of molecules marked with tritium and 14C.
Production of tritiated thymidine.
Production of 85Kr fire detectors.
Production of 60Co discs.
Production of 192Ir industrial radiography equipment.
Development of injectable radioactive preparations based on 59Fe, 47Ca, 197Hg and 85Sr, as well as 192Ir sutures and pins (brachytherapy).
Creation of the concept for a repetitive elution 99mTc dry generator.
Creation of the transport subsidiary company TRANSRAD.
Impact of Regionalization on some of the IRE’s activities:
Sale of the radiopharmaceutical product lines to the NORDION group.
Divestment of the sterilization and radioimmunology testing activities.
Refocusing of the IRE activity on the core businesses with the production of the medical radioisotopes 99Mo, 131I and 133Xe.
Major investments in the context of the redeployment of radiopharmaceutical activities.
Development of equipment for the remote monitoring of environmental radioactivity and radiological monitoring missions within the territory.
Support by IRE of the development of the company IBA, which also invested in the Fleurus site (R&D activities supported by a prototype 14 MeV SE cyclotron).
Important expansion of international commercial activities. In addition to the European market, IRE takes a significant role as a major stakeholder in North America, Asia, and the Middle East. This achievement provided IRE with a leadership position in the production of 99Mo and 131I.
Substantial investments in the renovation of installations in terms of safety, security and quality.
Creation of the IRE ELiT subsidiary.
New development in radiopharmaceutical activities in the diagnostic and therapy sectors (90Y, 188Re, 68Ga, etc.).
Major consultancy contracts worldwide (European Commission, IAEA, etc.).
New IRE communication policy in relation to its environment.
Growth in revenue from 2010 to 2015: 140%.
Growth in headcount from 2010 to 2015: 53%.
Launch of research partnerships worldwide.
First partnership with Belgian universities in the field of medical research.
Major participation in the NEA/OECD High-Level Group (HLG) on the Security of Supply of Medical Radioisotopes.
Important IRE role in AIPES (Association of Imaging Producers & Equipment Suppliers).
Participation in the BioWin Health Cluster of the Walloon region (southern part of Belgium).